Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC
Adding ipilimumab to pembrolizumab does not improve efficacy and is associated with greater toxicity than…
Browsing: Dr. Michael Boyer
Trending
- Making Telehealth Human – Podcast
- Sign Up for The Oncology Newsletter | Our free weekly news roundup
- Researchers illuminate potential precursors of blood cancers
- Attending consecutive mammography screens protects against breast cancer death
- Ambulatory function among cancer survivors: important determinant for survival
- Women in Global Oncology: Rachel Riechelmann
- Collagen plays protective role during pancreatic cancer development
- The OJC Episode 26: IASLC World Conference on Lung Cancer Part 2
- Mutant gene-targeted immunotherapy approach developed
- Genomic Data Commons provides unprecedented cancer data resource
